Key result
Clopidogrel therapy significantly reduced platelet aggregation evaluated with the Plateletworks assay (P<0.001) without affecting standard coagulation parameters in cats with asymptomatic HCM.
Why the study?
Does clopidogrel reduce platelet aggregation in cats with asymptomatic hypertrophic cardiomyopathy?
Population
14 asymptomatic cats with hypertrophic cardiomyopathy (HCM)
Comparison
Clopidogrel 18.75 mg/cat oral once daily for 7… vs Placebo
Design
Preclinical, randomly allocated, double-blind
Follow-up
7 days
Authors
Loading...
Hypothesis-generating for clopidogrel in feline HCM; leaves open clinical efficacy and outcome trials.
RCT (n=14)
double-blind
randomized
Does clopidogrel reduce platelet aggregation in cats with asymptomatic hypertrophic cardiomyopathy?
p-value: p=<0.001
Clopidogrel at 18.75 mg/cat daily for 7 days significantly decreases in vitro platelet aggregation evaluated with the Plateletworks assay in cats with asymptomatic HCM.
Toom et al. (2016) conducted an RCT in asymptomatic hypertrophic cardiomyopathy (n=14). clopidogrel vs. placebo was evaluated on aggregation responses to ADP and collagen in the Plateletworks® assay (p=<0.001). Clopidogrel therapy significantly reduced platelet aggregation evaluated with the Plateletworks assay (P<0.001) without affecting standard coagulation parameters in cats with asymptomatic HCM.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: